RESULTS:
There were approximately 6,161 plastic surgeons receiving 58,122 payments totaling $26,266,929. Approximately 87% of plastic surgeons nationwide received payment. The median payment per physician was $214. Payments to the top 10% of compensated plastic surgeons totaled $24,133,430 (92% total payments), and mean payment to these physicians was $39,177 (median = $7,793). Four-hundred sixty physicians (7.47%) received payments in excess of $5,000. Food and beverage was the most common payment type (80% total). Royalties or licenses received greatest amount of payment ($9,651,062; 36.75%). The greatest amount of payments was made in relation to botox ($6,659,335; 25.35%) . Allergan Inc. was the largest sponsor of nonresearch payments ($13,130,688; 50%) . Forty-six plastic surgeons received payments related to research totaling $497,063 (median, $1,638). The largest sponsor of research payments was Musculoskeletal Transplant Foundation INC ($251,730; 51%).
CONCLUSION:
The Physician Payments Sunshine Act makes conflicts of interest information more transparent and publically accessible. The majority of plastic surgeons received payment from industry. The most common forms of payment are food and beverage, but the largest overall payment is from royalties and licenses. Future studies associating physician behavior with conflicts of interest data may whether industry financial relationships influence provider care.
The Study on the Effect of Epidermal Growth Factor and Transforming Growth Factor-β1 in Intracellular Niche of Keloid Scar Fibroblast
Presenter: Sun Jae Lee, MD
Co-Authors: Seung Min Nam, MD, PhD; Eunsoo Park, MD, PhD; Young Woo Cheon, MD, PhD; Moon Seok Kang, MD; Jeong Jin Chun, MD Affiliation: Soonchunhyang University, Bucheon-si, Korea, Republic of (South)
PURPOSE: The treatment of keloid scars in not clearly established and causes many patients to suffer. Many studies have been conducted to differentiate keloids from normal skin. Previous studies have not directly addressed the effects of epidermal growth factor (EGF) and transforming growth factor (TGF)-β1 on keloid fibroblasts in an intracellular environment. In this study, we have investigated the effects of EGF and TGF-β1 on keloid fibroblasts in an intracellular environment.
MATERIALS AND METHODS:
The keloid tissues were collected from patients after surgical resection. Active and inactive keloids were differentiated based on clinical symptoms and keloid patterns. A total of 17 patients were enrolled, and 4 normal tissues, 8 inactive keloid tissues, and 5 active keloid tissues were obtained. From each tissue sample, fibroblasts were cultured without any stimulation and the expression of different biomarkers was estimated. The fibroblasts were then stimulated with 10 ng/ml of EGF and TGF-β1, and changes in the expression of the biomarkers were estimated using quantitative polymerase chain reaction.
RESULTS:
FSP-1, TGF-β1, α-SMA, and COL1A1 expression levels showed a difference of >2-fold and were highly expressed in active keloids. TGF-β1 expression was decreased in the active keloids after stimulation with EGF, and the TGF-β1 expression was increased in the inactive keloids. When stimulated with TGF-β1, the expression of α-SMA, COL1A1, and TGF-β1 was significantly increased in the active keloids, whereas the expression of TGF-β3 was decreased.
DISCUSSION:
The decreased expression of TGF-β1 and increased expression of TGF-β3 after TGF-β1 stimulation indicated a decrease in fibrotic factors and an increase in antifibrotic factors. Excessive stimulation of TGF-β1 is thought to stimulate the antifibrotic pathway. The addition of EGF led
